Ellory Kate Johnson, MD in Tuscaloosa, AL - General Practice

Ellory Kate Johnson, MD is a General Practice physician based in Tuscaloosa, Alabama. Ellory Kate Johnson is licensed to practice in Alabama (license number 1167) and her current practice location is 535 Jack Warner Pkwy Ne Ste G2, Tuscaloosa, Alabama. She can be reached at her office (for appointments etc.) via phone at (205) 771-2261.

NPI number for Ellory Kate Johnson is 1467144949 and her current mailing address is 4202 20th St Ne, Tuscaloosa, Alabama. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1467144949.

Contact Information

	Ellory Kate Johnson, MD
	535 Jack Warner Pkwy Ne Ste G2, Tuscaloosa, AL 35404-5715
	(205) 771-2261
	Not Available

Physician's Profile

Full Name	Ellory Kate Johnson
Gender	Female
Speciality	General Practice
Location	535 Jack Warner Pkwy Ne Ste G2, Tuscaloosa, Alabama
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1467144949
Provider Enumeration Date: 05/23/2023
Last Update Date: 05/23/2023

Medical Identifiers

Medical identifiers for Ellory Kate Johnson such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1467144949	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208D00000X	General Practice	1167 (Alabama)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Ellory Kate Johnson is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Ellory Kate Johnson, MD 4202 20th St Ne, Tuscaloosa, AL 35404-1502 Ph: (205) 771-2261	Ellory Kate Johnson, MD 535 Jack Warner Pkwy Ne Ste G2, Tuscaloosa, AL 35404-5715 Ph: (205) 771-2261

News Archive

Mayo Clinic researchers discover new bacterial species that triggers Lyme disease in people

Mayo Clinic researchers, in collaboration with the Centers for Disease Control and Prevention and health officials from Minnesota, North Dakota and Wisconsin, have discovered a new bacterial species that causes Lyme disease in people. The new species has been provisionally named Borrelia mayonii. Prior to this finding, the only species believed to cause Lyme disease in North America was Borrelia burgdorferi.

New model of inflammatory bowel disease explores interactions of cells in immune system

Scientists at the Virginia Bioinformatics Institute at Virginia Tech have constructed a mathematical and computational model of inflammatory bowel disease that allows researchers to simulate the cellular and molecular changes underlying chronic inflammation in humans. The model allows scientists to explore different interactions of cells in the immune system, check how these cells are linked to inflammation in the colon, and identify intervention points to perhaps stop the disease in its tracks.

A vitamin B pill that drastically lowers blood levels of homocysteine could one day be used to prevent dementia

High blood levels of homocysteine are a risk factor for stroke and dementia, including Alzheimer's disease. Raised levels damage nerves and blood vessels, and lead to a loss of brain tissue in patients.

Phase II human clinical trial of Exsulin commences

Exsulin Corporation today announced the start of a phase II human clinical trial of Exsulin, a peptide drug product aimed at restoring insulin production in people with diabetes mellitus. The randomized, controlled 12-week trial in patients with established Type 1 diabetes (T1DM) will be co-led by Mayo Clinic in Rochester, Minn., and McGill University Health Centre in Montreal, Canada.

IMBio receives regulatory concurrence from FDA to market OCL 500 microspheres in the U.S.

IMBiotechnologies Ltd., a privately held biotechnology company focused on developing medical device products for use in the area of embolotherapy, today announced that it has received regulatory concurrence from the United States Food and Drug Administration to market its lead product, Occlusin 500 Artificial Embolization Device in the U.S. for the treatment of unresectable/inoperable hypervascularized tumours.

General Practice Doctors in Tuscaloosa, AL

Kristen Pleshette Williams, General Practice Medicare: Medicare Enrolled Practice Location: 922 Fairfax Park, Tuscaloosa, AL 35406 Phone: 205-391-9300
Katherine Caroline Mcvinnie, MD General Practice Medicare: Medicare Enrolled Practice Location: 200 University Blvd, Bryce Hospital, Tuscaloosa, AL 35401 Phone: 205-759-0799 Fax: 205-759-0845

Ellory Kate Johnson, MD - General Practice in Tuscaloosa, AL